bullish
Kronos Bio IPO. Gilead’s SYK Inhibitor Portfolio Will Boost The Pipeline
416 Views09 Oct 2020 17:36
A clinical-stage biotech company Kronos Bio, founded by partners and executives from Two River Group, priced its IPO of ~13.1 million shares at...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 18-minute read)
Discussions
(Paid Plans Only)
Rising
Andrei Zakharov
Covering IPOs, Healthcare and Technology Stocks
- Kronos Bio IPO. Gilead’s SYK Inhibitor Portfolio Will Boost The Pipeline09 Oct 2020
x